By Brazil Stock Guide — Brazilian publicly traded education group Ânima Educação (B3: ANIM3) announced on Monday (October 19) a long-term agreement between its medical education subsidiary, Inspirali, and Albert Einstein Hospital, one of Brazil’s leading healthcare institutions, to improve teaching standards across its medical schools following disappointing results in a nationwide government assessment.
The agreement includes fixed payments totaling R$150 million, revenue-sharing payments tied to new student enrollment, and additional compensation linked to future conditions. It comes as Brazilian education authorities tighten oversight of medical schools, with poorly rated institutions facing potential cuts to student admissions and other regulatory restrictions.
Inspirali operates 15 medical education institutions across Brazil, with approximately 12,600 students and 1,892 authorized annual admission slots. Its regulatory filings acknowledge that several schools performed poorly in the 2025 National Medical Education Assessment Exam, known as Enamed.
Administered by Brazil’s Ministry of Education, Enamed evaluates the quality of undergraduate medical training. Programs receive ratings on a scale of 1 to 5, with 5 representing the highest performance. Scores of 1 or 2 are considered unsatisfactory and may trigger regulatory scrutiny.
Inspirali’s 2026 regulatory filing reported that four schools received a rating of 2 and one received a rating of 1. However, a review of the published examination results identifies six medical programs within the group’s network with unsatisfactory scores: five rated 2 and one rated 1.
Three of the poorly rated programs belong to Universidade Anhembi Morumbi, in São Paulo, Piracicaba and São José dos Campos, all of which received a rating of 2. Faculdade da Saúde e Ecologia Humana (FASEH), in Vespasiano, Minas Gerais, received the lowest rating of 1. Two medical schools operated under the Ages brand, in Jacobina and Irecê, in the northeastern state of Bahia, also received ratings of 2.
These results carry potential financial consequences. Under Brazil’s regulatory framework, poorly performing medical schools may face restrictions on new admissions, reductions in authorized enrollment capacity, and limitations on participation in federally supported student financing programs.
In August, Brazil’s Superior Court of Justice cleared the Ministry of Education to resume using the 2025 Enamed results to supervise medical schools, suspending a lower court decision that had temporarily blocked such oversight. The ruling restored the regulator’s ability to act on the examination results while the underlying legal dispute continues.
For private education companies, restrictions on authorized medical school places can directly affect future revenue, making academic performance an increasingly important business consideration.
Inspirali has acknowledged the regulatory risks. In its 2026 regulatory filing, the company said it had established an academic performance monitoring program overseen by an executive committee that meets weekly. The initiative focuses on reviewing student outcomes, strengthening curricula, improving academic management and mitigating regulatory risks.
The company has not explicitly linked its disappointing Enamed results to the decision to enter into the Einstein partnership.
Under the agreement, Einstein will provide exclusive technical, scientific and educational consulting services to Inspirali’s medical schools. The services will include curriculum development, faculty training, academic assessment and improvements to medical education practices.
Inspirali will also be authorized to associate the Einstein brand with its medical degree programs, subject to contractual conditions. The arrangement may be extended to institutions subsequently established, acquired or incorporated into the group.
The contract has an initial term of 20 years and provides for automatic renewal for another two decades, potentially creating a 40-year relationship between the two organizations.
The financial structure includes a fixed payment of R$150 million, divided into two installments of R$75 million. The first is payable upon signing, while the second is due one year later and will be adjusted for inflation using Brazil’s IPCA consumer price index.
Einstein will also receive revenue-sharing payments equivalent to 6% of net revenue generated by students entering medical school classes that begin after the agreement’s signing. These payments will be calculated and settled quarterly.
The contract provides for additional compensation between 2027 and 2036, subject to certain future conditions. The combined maximum annual amounts under this component total R$332.1 million, expressed in December 2026 prices and subject to inflation adjustments.
Those additional payments are not guaranteed. They depend partly on the revenue-sharing amounts generated each year and are subject to contractual limits.
Ânima, which owns approximately 74% of Inspirali, said the initial R$75 million cash payment would increase its leverage ratio from 2.41 times, as reported in the second quarter of 2026, to 2.47 times on a pro forma basis.
The company did not provide an estimate of the agreement’s total cost over its initial 20-year term, as a significant portion of the compensation will depend on future student-related revenue.
For Einstein, a nonprofit healthcare, research and education organization founded in 1955, the agreement creates a long-term revenue stream and expands the reach of its brand in Brazil’s private medical education market.
Einstein’s own undergraduate medical program received the highest possible rating of 5 in the 2025 Enamed examination, placing it among the country’s best-performing medical schools.
Despite the association, Einstein will not assume management or decision-making authority over Inspirali’s institutions. Responsibility for operating the programs, issuing medical degrees, complying with regulatory requirements and managing relationships with students and faculty will remain exclusively with Inspirali.
The Einstein name will therefore not replace regulatory approval or exempt the participating schools from future government assessments.
For Ânima, the agreement represents a long-term investment in academic quality and brand differentiation at a time when regulatory performance is becoming increasingly important to the economics of Brazil’s medical education business.
The challenge will be to translate Einstein’s expertise and reputation into measurable improvements in student performance, strengthen the competitive position of Inspirali’s schools and justify the substantial financial commitments of a partnership that could extend over four decades.
Leave a Reply